Revenue Soars, Profit Slips
Torrent Pharmaceuticals’ consolidated net profit for the quarter ended September 30 fell to 5.34 billion rupees from 5.91 billion rupees a year earlier. The paradox is that revenue rose strongly, but costs rose even faster. Key figures for the quarter include:
- Total revenue up nearly 51% to 49.79 billion rupees.
- Total expenses up about 71%, including a 35% rise in research and development costs.
- Profit margin down to 10.7% from 17.9% a year earlier.
The picture shows Torrent accepting a short-term sacrifice in profit to invest in new products and scale – a familiar choice for drugmakers at a turning point.
The Domestic Market as the Main Engine
Sales in India, Torrent’s biggest market, jumped 20% to 21.81 billion rupees. Along with peers such as Mankind Pharma, Torrent continues to benefit from strong demand for chronic therapies, particularly diabetes and cardiovascular treatments, helping drive steady growth in its domestic formulations business.















